A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

Also called NCT04865770

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 106 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04865770
  • EudraCT 2020-000828-19
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Denmark, France, Italy, Poland, South Africa, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04865770. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-28 (actual); primary completion 2024-11-21 (actual). Results posted on 2026-01-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
Acronym
REMODEL
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo (Semaglutide)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04865770
Content hash
201b2b73e04f179101e3414f08ae1ad34a7954da3ecd10a25f4818b7c8da84a6